Rivoroxaban
Phase 3Small molecule
Rivoroxaban is one of 20 small molecule programs targeting Venous thrombosis. It is currently in Phase 3.
2
Indications
2
Total Trials
1
Active Trials
19
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
20 competitors in Venous Thrombosis
#DrugCompanyPhaseTrials
1Eliquis
Bristol-Myers SquibbApproved
Bayer Aspirin
BayerApproved
Arixtra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Intravenous Thrombolysis
SSecond Affiliated Hospital, School of Medicine, Zhejiang University
Phase 3
Anticoagulation Agents
IInari Medical
Phase 3
Rivoroxaban
FFoundation University Islamabad
Phase 3
Lovenox
SanofiPreclinical
Medrol
PfizerPreclinical
Crestor
AstraZenecaPreclinical
Tecentriq
RochePreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Rivaroxaban1 trial
Rivaroxaban vs Warfarin in Patients With Mechanical Heart Valves
Enrolling by invitation·—·Phase 3·NCT07456085·60 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Rivoroxaban. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- FFoundation University Islamabad